Bristol Sprycel Receives Broad Committee Support For Leukemia Indications

FDA’s Oncologic Drugs Advisory Committee votes unanimously in favor of dasatinib approval for all phases of Gleevec-resistant or intolerant CML.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet